STAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancer

Coverage, in order

1. 16d ago
   
   first STAT News indie study randomized trial

   STAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancer

   MADRID — A type of targeted chemotherapy developed by Merck and China’s Kelun-Biotech cut by one-third the risk of death in patients with advanced endometrial cancer, a common gynecological cancer, according to randomized Phase 3 study results presented Monday. The drug, called sacituzumab…

2. 15d ago
   
   The Hindu Health India mainstream review

   Merck drug extends survival in endometrial cancer trial, wins U.S. priority review

   The drug delivers a cancer-killing payload to cells that carry a protein common in endometrial tumours

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.